Radioiodine treatment of hyperthyroidism: Fixed or calculated doses; Intelligent design or science? [2]

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 7, 2007, Pages 1129-1130

  Sisson, James C ^a   Avram, Anca M ^a   Rubello, Domenico ^b   Gross, Milton D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Ospedale S Maria della Misericordia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; PROPYLTHIOURACIL; THIAMAZOLE;

DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; DRUG UPTAKE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LETTER; LOW DRUG DOSE; RADIATION ABSORPTION; RADIATION EXPOSURE; RADIOACTIVITY; RADIOSENSITIVITY; THYROID CANCER;

DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 34250317440     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0419-0     Document Type: Letter

References (15)

1. Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radiodiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001;86:3611-7.
2. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003;88:978-83.
3. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Saimi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol 2004;61:641-8.
4. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioioidine; results of a prospective study. Thyroid 1997;2:247-51.
5. Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy of Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 2002;29:1118-24.
6. 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87:1073-7.
7. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Brit Med J 1984;289:361-3.
8. IRCP. Protection of the patient in medicine. IRCP publication 52. Ann IRCP 1987;17 4:5. New York: Pergamon Press.
9. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998;280:347-55.
10. Pollycove M, Feinendegen LE. Biologic responses to low doses of ionizing radiation: detrement versus hormesis. Part 2. Dose responses in organisms. J Nucl Med 2001;42:26N-37N.
11. IRCP. Radiation dose to patients from radiopharmaceuticals. ICRP publication 53. Ann IRCP 1994;278. New York: Pergamon Press.
12. Willemsen UF, Knewewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with 300-Gy absorbed dose in Graves' disease. Eur J Nucl Med 1993;20:1051-5.
13. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, et al. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 1999;9:865-9.
14. Lucas KJ. Use of ultrasound volume in calculating radioactive iodine dose in hyperthyroidism. Thyroid 2000;10:151-5.
15. 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25:186-93.